A nurse is caring for a client who has a new prescription for pramipexole to treat parkinsons

1. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med. 1998;339:1044–1053. [PubMed] [Google Scholar]

2. Gibb WR. Neuropathology of Parkinson’s disease–related syndromes. Neurol Clin. 1992;10:361–376. [PubMed] [Google Scholar]

3. Fearnley J, Lees A. Pathology of Parkinson’s disease. In: Calne DB, editor. Neurodegenerative Diseases. Philadelphia, PA: WB Saunders; 1994. pp. 545–554. [Google Scholar]

4. Braak H, Braak E. Pathology of Alzheimer’s disease. In: Calne DB, editor. Neurodegenerative Diseases. Philadelphia, PA: WB Saunders; 1994. pp. 585–614. [Google Scholar]

5. National Parkinson Foundation About Parkinson disease: Who gets Parkinson’s disease? April 2008. Available at: www.parkinson.org/netcommunity/page.aspx?pid=225&srcid=201

6. Albin RL. Parkinson’s disease: Background, diagnosis, and initial management. Clin Geriatr Med. 2006;22:735–751. [PubMed] [Google Scholar]

7. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999:1214–1220. [PubMed] [Google Scholar]

8. LeWitt PA. Tobacco smoking, nicotine, and neuroprotection. In: Factor SA, Weiner WJ, editors. Parkinson’s Disease: Diagnosis and Clinical Management. New York: Demos; 2002. pp. 519–529. [Google Scholar]

9. Hardy J, Cookson MR, Singleton A. Genes and parkinsonism. Lancet Neurol. 2003;2:221–228. [PubMed] [Google Scholar]

10. National Institute of Neurological Disorders and Stroke Available at: www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm April 2008. Accessed May 3, 2008. [Google Scholar]

11. Ruane C.What is Parkinson’s disease?Available at: www.ezilon.com/information/printer_15984.shtml February 2006. Accessed May 3, 2008.

12. Aminoff MJ. Pharmacologic management of parkinsonism and other movement disorders. In: Katzung BG, editor. Basic and Clinical Pharmacology. 10th ed. New York: McGraw-Hill Lange Medical; 2007. pp. 442–451. [Google Scholar]

13. Hauser R. Long-term care of Parkinson’s disease: Strategies for managing ‘wearing off’ symptom re-emergence and dyskinesias. Geriatrics. 2006;61:14–20. [PubMed] [Google Scholar]

14. Alam ZI, Daniel SE, Lees AJ, et al. A generalized increase in protein carbonyls in the brain of Parkinson’s but not incidental Lewy body disease. J Neurochem. 1997;69:1326–1329. [PubMed] [Google Scholar]

15. LeWitt PA. Parkinson’s disease: Etiologic considerations. In: Ahlskog JE, Adler CA, editors. Parkinson’s Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician. New York: Humana Press; 2000. pp. 91–100. [Google Scholar]

16. Leegwater-Kim J, Waters C. Parkinsonism. In: Rakel RE, Bope ET, editors. Conn’s Current Therapy. Philadelphia: WB Saunders, Elsevier; 2008. pp. 931–936. [Google Scholar]

17. Di Fonzo A, Tassorelli C, De Mari M, et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease. Eur J Hum Genet. 2006;14:322–331. [PubMed] [Google Scholar]

18. Whaley NR, Uitti RJ, Dickson DW, et al. Clinical and pathologic features of families with LRRK2-associated Parkinson’s disease. J Neural Transm Suppl. 2006;(70):221–229. [PubMed] [Google Scholar]

19. Mata IF, Wedemeyer WJ, Farrer MJ, et al.LRRK2 in Parkinson’s disease: Protein domains and functional insights Trends Neurosci 2006295286–293.Electronic version, April 17, 2006. [PubMed] [Google Scholar]

20. Nelson MV, Berchou RC, LeWitt PA. Parkinson’s disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy, A Physiologic Approach. 6th ed. New York: McGraw-Hill; 2005. pp. 1075–1088. [Google Scholar]

21. Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376. [PubMed] [Google Scholar]

22. Kawahara K, Hashimoto M, Bar-On P, et al. Alpha-synuclein aggregates interfere with parkin solubility and distribution: Role in the pathogenesis of Parkinson’s disease. J Biol Chem. 2008;283(11):6979–6987. [PubMed] [Google Scholar]

23. Fahn S. Parkinson’s disease and related disorders. In: Hazzard WR, Blass JP, Halter JB, et al., editors. Principles of Geriatric Medicine and Gerontology. New York: McGraw-Hill; 2003. pp. 1401–1408. [Google Scholar]

24. Ahlskog JE. Parkinson’s disease: Medical and surgical treatment. Hurtig HI, Stern MB, editors. Neurol Clin Mov Disord. 2001;19(3):579–605. [PubMed] [Google Scholar]

25. Michigan Parkinson foundation Available at www.parkinsonsmi.org/facts.asp#5 Accessed September 12, 2008.

26. Hirsch ML.Cognitive changes in Parkinson’s disease. American Parkinson Disease Association, 2008. Available at: www.waparkinsons.org/edu_research/articles/Cognitive_Changes.html Accessed May 3, 2008.

27. Marsh L.Not just a movement disorder: Cognitive changes in PD. Parkinson’s Disease Foundation, Winter 2007–2008. Available at: www.pdf.org/Publications/newsletters/winter07_08/Not_Just_a_Movement.cfm Accessed May 3, 2008.

28. Galvin JE. Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord. 2006;20:302–310. [PubMed] [Google Scholar]

29. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. pp. 503–519. [Google Scholar]

30. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–458. [PubMed] [Google Scholar]

31. Stalevo, prescribing information, Novartis. Available at: www.pharma.us.novartis.com/product/pi/pdf/stalevo.pdf Accessed April 2008.

32. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one-month double blind study in parkinsonian patients with levodopa-related fluctuations. J Neurol Neurosurg Psychiatry. 1996;60:36–40. [PMC free article] [PubMed] [Google Scholar]

33. Frucht S, Rogers JG, Greene PE, et al. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908–1910. [PubMed] [Google Scholar]

34. Parkinson Study Group Pramipexole vs. levodopa as initial treatment for Parkinson’s disease: A randomized, controlled trial. JAMA. 2000;284:1931–1938. [PubMed] [Google Scholar]

35. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342:1484–1491. [PubMed] [Google Scholar]

36. Ropinirole (Requip), prescribing information. GlaxoSmithKline, October 2006. Available at: http://us.gsk.com/products/assets/us_requip.pdf Accessed September 9, 2008.

37. Pramipexole (Mirapex), prescribing information, Boehringer Ingelheim. Available at: http://bidocs.boehringer-ingelheim.com Accessed September 25, 2008.

38. Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson’s disease: A review. Exp Opin Pharmacother. 2007;8:2799–2809. [PubMed] [Google Scholar]

39. Apomorphine (Apokyn), prescribing information, Vernalis. Available at: www.drugs.com/pro/apokyn.html Accessed September 25, 2008.

40. Rotigotine Transdermal System (Neupro). Schwarz Pharma. Available at: www.schwarzpharma.com Accessed May 5, 2008.

41. Parkinson Study Group Entacapone improved motor fluctuations in levodopa-treated Parkinson’s disease patients Ann Neurol 199742744–755.Erratum, Ann Neurol 1998;44:292. [Google Scholar]

42. Kurth MC, Adler CH, Hillarie MS, et al. Tolcapone improved motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: A multimember, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuate Study Group 1. Neurology. 1997;48:81–87. [PubMed] [Google Scholar]

43. Tolcapone (Tasmar), prescribing information, Valeant. Available at: www.valeant.com/fileRepository/products/PI/Tasmar_PI_Feb_2006.pdf Accessed September 15, 2008.

44. Entacapone (Comtan), prescribing information, Novartis. Available at: www.pharma.us.novartis.com/product/pi/pdf/comtan.pdf Accessed September 15, 2008.

45. Olanow CW. MAO-B inhibitors in Parkinson’s disease. Adv Neurol. 1993;60:666–671. [PubMed] [Google Scholar]

46. Waters CH, Sethi KD, Hauser RA, et al. Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426–432. [PubMed] [Google Scholar]

47. Coelho M, Ferreira J, Sampaio C. Parkinson’s disease. In: Candelise L, Hughes R, Liberati A, et al., editors. Evidence-Based Neurology: Management of Neurological Disorders. Malden, MA: Blackwell Publishing; 2007. [Google Scholar]

48. Chen JJ, Swope DM. Pharmacotherapy for Parkinson’s disease. Pharmacotherapy. 2007;27:161S–173S. [PubMed] [Google Scholar]

49. deMarcaida JA, Schwid SR, White WB, et al.the Parkinson Study Group TEMPO and PRESTO Tyramine Substudy Investigators and Coordinators Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21:1716–1721. [PubMed] [Google Scholar]

50. Olanow CW, Rascol O.Early rasagiline treatment slows UPDRS decline in the ADAGIO delayed-start study. Presented at the 133rd annual meeting of the American Neurological Association, Salt Lake City, Utah, September 21–24, 2008. Available at: www.abstracts2view.com/ana

51. Horn JR, Hansten PD. Preventing rasagiline drug interactions. Pharmacy Times. 2007;73(1):80. [Google Scholar]

52. Cogentin, adverse effects. WebMD. Available at: www.webmd.com/drugs/drug-279-Cogentin+Inj.aspx?drugid=279&drugname=Cogentin+Inj&pagenumber=6 Accessed September 15, 2008.

53. Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson’s disease. Pharmacol Ther. 2004;102:155–174. [PubMed] [Google Scholar]

54. Amantadine (Symmetrel), prescribing information, Endo, 2003. Available at: www.endo.com/PDF/amantadine_pack_insert.pdf Accessed September 16, 2008.

55. Cantuti-Castelvetri I, Standaert DG. Neuroprotective strategies for Parkinson’s disease. Curr Neuropharm. 2004;2:153–168. [Google Scholar]

56. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol. 2002;59:1937–1943. [PubMed] [Google Scholar]

57. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541–1550. [PubMed] [Google Scholar]

58. Storch A, Jost WH, Vieregge P, et al.Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease Arch Neurol 2007647938–944.Electronic version, May 14, 2007. [PubMed] [Google Scholar]

59. Romano CJ.Levodopa and Parkinson’s disease progression: Contradictory results from the ELLDOPA study. Neurologyreviews.com, 2003116 [Google Scholar]

Page 2

Levodopa Drug Combinations for the Treatment of Parkinson’s Disease